Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 1250 Waverley Street WINNIPEG MB R3T 6C6 |
Tel: | N/A |
Website: | https://www.medicure.com |
IR: | See website |
Key People | ||
Albert D. Friesen Chairman of the Board, Chief Executive Officer | Neil Owens President, Chief Operating Officer | Haaris Uddin Chief Financial Officer |
Business Overview |
Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). |
Financial Overview |
For the nine months ended 30 September 2023, Medicure Inc revenues decreased 1% to C$16.6M. Net income applicable to common stockholders decreased 31% to C$627K. Revenues reflect Marketing & Distribution of Commercial Products segment decrease of 15% to C$9.5M. Net income also reflects Selling/General/Admin Expense increase of 22% to C$5.4M (expense), Change in fair value of contingent consi decrease from C$302K (income) to C$0K. |
Employees: | 25 as of Dec 31, 2022 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $8.52M as of Sep 30, 2023 |
Annual revenue (TTM): | $22.94M as of Sep 30, 2023 |
EBITDA (TTM): | $3.33M as of Sep 30, 2023 |
Net annual income (TTM): | $1.08M as of Sep 30, 2023 |
Free cash flow (TTM): | $1.47M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 10,436,313 as of Sep 30, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |